Program
onfekafusp alfa
Also written as “L19TNF”, “Onfekafusp alfa” and “L19TNF and TMZ”.
Its studies are mostly in Glioblastoma · Melanoma · Sarcoma · Carcinoma, Basal Cell · Glioma, led by Philogen.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Philogen | 1512 open or running | phase 3since Oct 11, 2016 | Feb 24, 2014 | Jul 2028phase 2 · NCT06284590 |
Also a collaborator on its studies: Merck.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 1 study since Feb 24, 2014.
- Oct 11, 2016Phase 3 study in MelanomaNCT02938299 · 214 enrolled · France, Germany, Italy and more
- Jan 12, 2018Phase 2 study in LeiomyosarcomaNCT03420014 · 114 planned · United States
- Dec 14, 2018Phase 2 study in Glioma of BrainNCT03779230 · 20 enrolled · Switzerland
- Jun 28, 2019Phase 1 study in SarcomaNCT04032964 · 2 enrolled · United States
- Apr 17, 2020Phase 2 study in Carcinoma, Basal CellNCT04362722 · 40 planned · Germany, Poland, Switzerland
- Jun 17, 2020Phase 2 study in GlioblastomaNCT04443010 · 226 planned · Switzerland
- Sep 25, 2020Phase 2 study in GlioblastomaNCT04573192 · 142 planned · France, Germany, Italy and more
- Nov 25, 2020Phase 3 study in SarcomaNCT04650984 · 102 planned · France, Germany, Italy and more
- Jan 22, 2021Phase 2 study in SarcomaNCT04733183 · 98 enrolled · France, Germany, Italy and more
- Feb 24, 2022Phase 1 study in GlioblastomaNCT05304663
- Jan 26, 2024Phase 2 study in MelanomaNCT06284590 · 162 planned · United States, Germany, Italy
- Mar 4, 2024Phase 2 study in GlioblastomaNCT06336291 · 90 enrolled · United States
- Jul 30, 2025Phase 2 study in GliomaNCT07120984 · 52 planned
- Nov 7, 2025Phase 2 study in Carcinoma, Basal CellNCT07227350 · 180 planned · United States, Germany, Greece and more
Ahead
- Jul 2028Primary completion: phase 2 study in MelanomaNCT06284590
- Jan 30, 2029Primary completion: phase 2 study in GliomaNCT07120984
- Feb 2031Primary completion: phase 2 study in Carcinoma, Basal CellNCT07227350
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 15 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07227350Carcinoma, Basal Cell · United States, Germany, Greece and more | 2 | Recruiting | Feb 2031 | 180 |
| NCT07120984Glioma | 2 | Not yet recruiting | Jan 30, 2029 | 52 |
| NCT06336291Glioblastoma · United States | 2 | Active, not recruiting | Jun 2026 | 90 |
| NCT06284590Melanoma · United States, Germany, Italy | 2 | Recruiting | Jul 2028 | 162 |
| NCT05304663Glioblastoma | 1 | Withdrawn | Dec 31, 2024 | 0 |
| NCT04733183Sarcoma · France, Germany, Italy and more | 2 | Active, not recruiting | Dec 2025 | 98 |
| NCT04650984Sarcoma · France, Germany, Italy and more | 3 | Recruiting | Dec 31, 2025 | 102 |
| NCT04573192Glioblastoma · France, Germany, Italy and more | 2 | Recruiting | Mar 2025 | 142 |
| NCT04443010Glioblastoma · Switzerland | 2 | Recruiting | Oct 2026 | 226 |
| NCT04362722Carcinoma, Basal Cell · Germany, Poland, Switzerland | 2 | Recruiting | Sep 2024 | 40 |
| NCT04032964Sarcoma · United States | 1 | Active, not recruiting | Dec 2024 | 2 |
| NCT03779230Glioma of Brain · Switzerland | 2 | Completed | Jun 27, 2023 | 20 |
| NCT03420014Leiomyosarcoma · United States | 2 | Recruiting | Dec 2024 | 114 |
| NCT02938299Melanoma · France, Germany, Italy and more | 3 | Active, not recruiting | Oct 2024 | 214 |
| NCT02076633Melanoma · Italy | 2 | Completed | May 2015 | 21 |
How it is read
Names in the registry
- “L19TNF”, 9 entries
- “Onfekafusp alfa”, 3 entries
- “L19TNF and TMZ”, 1 entry
- “L19TNF and CCNU”, 1 entry
- “L19TNF monotherapy”, 1 entry
Conditions, from the studies’ own filings
- Glioblastoma, 4 studies
- Melanoma, 3 studies
- Sarcoma, 3 studies
- Carcinoma, Basal Cell, 2 studies
- Glioma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.